Stock comparison
Genmab A/S
GSK
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
GSK
GSK
Market cap
$103.33B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | GSK | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 58C | GMAB |
| Benjamin Graham | 64C | 62C | GMAB |
| Philip Fisher | 48D | 66B | GSK |
| Peter Lynch | 25F | 47D | GSK |
| Joel Greenblatt | 76B | 35D | GMAB |
| Charlie Munger | 68C | 65C | GMAB |
| Terry Smith | 71C | 63C | GMAB |
Side-by-side metrics
| Metric | GMAB | GSK |
|---|---|---|
| Market cap | $16.5B | $103.33B |
| P/E (TTM) | 6.2x | 12.9x |
| EV/EBIT | 12.0x | 10.8x |
| ROIC (TTM) | 43.78% | 13.76% |
| Gross margin | 93.88% | 72.74% |
| Net margin | 18.23% | 17.78% |
| Revenue CAGR 5y | -18.45% | 7.24% |
| EPS CAGR 5y | -23.48% | 19.78% |
| Debt / Equity | 0.1x | 1.1x |
| Dividend yield | 0.0% | 3.6% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 1.1x+93%
- ROIC (TTM)43.78%vs 13.76%+69%
- P/E (TTM)6.2xvs 12.9x+52%
- Gross margin93.88%vs 72.74%+23%
GSK leads on
- EPS CAGR 5y19.78%vs -23.48%+184%
- Revenue CAGR 5y7.24%vs -18.45%+139%
- Dividend yield3.6%vs 0.0%+100%
- Market cap$103.33Bvs $16.5B+84%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.